Home

Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae

rCap expressed in T. ni larvae could be a cost-effective PCV2 vaccine candidate to be tested under field conditions.

Porcine circovirus type 2 (PCV2) vaccination has been recently included as a measure to control postweaning multisystemic wasting syndrome (PMWS) in the field. Aiming to obtain a more affordable vaccine to be extensively implemented in the field, a highly efficient non-fermentative expression platform based on Trichoplusia ni (T. ni) larvae was used to produce a baculovirus-derived recombinant PCV2 Cap protein (rCap) for vaccine purposes. Vaccination of pigs with rCap induced solid protection against PCV2 experimental infection, inhibiting both the viremia and the viral shedding very efficiently.

The protection afforded by the rCap vaccine strongly correlated with the induction of specific humoral immune responses, even in the presence of PCV2-specific maternal immunity, although cellular responses also seemed to play a partial role.

In summary, we have shown that rCap expressed in T. ni larvae could be a cost-effective PCV2 vaccine candidate to be tested under field conditions.

Pérez-Martín E, Gómez-Sebastián S, Argilaguet JM, Sibila M, Fort M, Nofrarías M, Kurtz S, Escribano JM, Segalés J, Rodríguez F. Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae. Vaccine. 2010 Mar 8;28(11):2340-9.

Article Comments

This area is not intended to be a place to consult authors about their articles, but rather a place for open discussion among pig333.com users.

Leave a new Comment

Access restricted to 333 users. In order to post a comment you must be logged in.

You are not subscribed to this list pig333.com in 3 minutes

Weekly newsletter with all the pig333.com updates

Home

HealthArticle

Maternally derived antibodies at the time of porcine circovirus type 2 vaccination: does it matter?

One issue is to overcome maternal immunity, which is true for all PCV2 vaccines in the market, and another is whether the most from these vaccines is achieved independently of the PCV2 antibody titre at vaccination

Home

HealthArticle

Prevention and control of porcine circovirus

We may have some highly efficient vaccines, but we shouldn’t forget that for their application we must obtain good diagnostic information, and that in all cases we should not lose sight of good management and a good control of the concomitant diseases.

Home

HealthArticle

Immunology against PCV2: What difference is there between a subclinically affected animal and an animal with porcine circovirus?

Pigs that are not affected by the disease tend to have a quantity of sero-neutralizing (and also total) antibodies against PCV2, which is significantly greater than those that cause disease

Welcome to 333

Connect, share, and interact with the largest community of professionals in the swine industry.

Celebrating 153619Users on 333!

Immunity conferred by an experimental vaccine based on the recombinant PCV2 Cap protein expressed in Trichoplusia ni-larvae

Article Comments

Related articles

Maternally derived antibodies at the time of porcine circovirus type 2 vaccination: does it matter?

Prevention and control of porcine circovirus

Immunology against PCV2: What difference is there between a subclinically affected animal and an animal with porcine circovirus?

African Swine Fever

Diseases manual

Pig prices

Feed commodity prices

Pig production data

Water medication calculator

The most...

tags